Abstract
322 Background: YouTube is an open-access source of information. It has more than 2.5 billion users. It can play a pivotal role in educating or misinforming our cancer patients. Emerging therapeutics like BsAbs have changed the treatment paradigm for cancer over the past decade. There is scarce data to evaluate the quality of information on BsAbs uploaded on YouTube. We aim to assess the quality and engagement parameters of the most viewed videos on YouTube. Methods: A systematic search was conducted on YouTube using the search terms (“bispecific antibodies” AND “cancer”). The 70 most viewed videos were selected only in the English language. We utilized the already validated PEMAT and DISCERN tools to assess the quality of these videos on BsAbs. Additionally, we looked at the number of views, comments, and likes. Descriptive statistics and Pearson correlation tests were performed using R studio v2022.12.0-353. Results: The videos in our study had up to 50,000 views (, and the overall quality of information was poor (46.38%). These videos were categorized into different sources academic (61%), media (14.5%), and commercial (24.5%). Only 27.5% of videos discussed the benefits, 17% discussed the risks, 8.7% discussed the effect on the quality of life (QoL), and 11% discussed shared decision-making. Financial barriers were discussed only in 4% of the videos, whereas the availability of the drug was discussed in 11% of the videos. Regarding side effects, 32% of videos mention cytokine release syndrome, while 20% mention neurological toxicity. The mean DISCERN score for the videos was 41.2. A significant trend of increased DISCERN and PEMAT scores was noticed with the increasing length of the videos. Conclusions: This is the first study to evaluate the quality of information on BsAbs on YouTube. This study highlights the poor quality of information available on YouTube; these videos are less likely to discuss the risks, effects on QoL, and shared decision-making. Further efforts are needed to improve the quality and engagement of these videos based on the validated scales.[Table: see text]
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
